More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo.
The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise.
